Bright Minds Biosciences Inc (DRUG) — Smart Money Tracker (13F, Q2 2026)

DRUG ranks #4550 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

102 institutions disclose a position in DRUG, but none treat it as a major bet — even Acuta Capital Partners, LLC, its most concentrated holder, allocates just 4.5% of its own portfolio to it.

BlackRock has added to its DRUG position for two straight quarters, increasing it by $17.4M to reach $48.2M today.

Cormorant Asset Management, LP has trimmed its DRUG position for two straight quarters, cutting it by $19.5M while still holding $63.2M.

DRUG is up 0.4% today, and institutions have been net buyers of $36.7M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

DRUG reported a net loss of $2.8M in its latest fiscal year.

• Not yet profitable — net loss of $2.8M in the latest fiscal year
• Net income improved year over year, from -$7.4M to -$2.8M
• Operating cash flow was negative, using $1.9M in cash
• Current ratio of 11.32x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.10x equity — within a conventional range